Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al. CD20 is associated with a small mature plasma-cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070–1071.

    Article  CAS  Google Scholar 

  2. Linenberger ML . CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005; 19: 176–182.

    Article  CAS  Google Scholar 

  3. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, for the Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.

    Article  CAS  Google Scholar 

  4. Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655–1665.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Epstein J, Xiao HQ, He XY . Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med 1990; 322: 664–668.

    Article  CAS  Google Scholar 

  6. Freeman SD, Kelm S, Barber EK, Crocker PR . Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995; 85: 2005–2012.

    CAS  Google Scholar 

  7. Paul SP, Taylor LS, Stansbury EK, McVicar DW . Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96: 483–490.

    CAS  Google Scholar 

  8. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al., for the Intergroupe Francophone du Myélome (IFM). Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation. Blood 2002; 99: 2185–2191.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the Ligue contre le Cancer.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H Avet-Loiseau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robillard, N., Wuillème, S., Lodé, L. et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia 19, 2021–2022 (2005). https://doi.org/10.1038/sj.leu.2403948

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403948

This article is cited by

Search

Quick links